Higher expression of estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER1/HER2-breast cancerBackground: Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with ...